1. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. (20th October 2022) Authors: Concin, Nicole; Patel, Manish R; Makker, Vicky; Oaknin, Ana; Pignata, Sandro; Backes, Floor J; González-Martín, Antonio; Eskander, Ramez N; Pothuri, Bhavana; Richardson, Debra L; Secord, Angeles Alvarez; van Nieuwenhuysen, Els; Liu, Joyce F; Musa, Fernanda; Penson, Richard T; Wride, Kenton; Dusek... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗